Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 4/20 | 0.37 |
| ▸ | PRKCA | P17252 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.34 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
| ▸ | PRKACA | P17612 | 1/20 | 0.34 |
| ▸ | PRKACG | P22612 | 1/20 | 0.34 |
| ▸ | PRKACB | P22694 | 1/20 | 0.34 |
| ▸ | CCND1 | P24385 | 1/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flosequinan SCHEMBL5442796 | 1.00 | ATM (0.47) | ATMKDM4EALDH1A1IDO1TDO2 | |
| Flosequinan SCHEMBL5441172 | 1.00 | ATM (0.47) | ATMKDM4EALDH1A1IDO1TDO2 | |
| Flosequinan SCHEMBL6535622 | 0.99 | ATM (0.46) | ATMKDM4EALDH1A1IDO1TDO2 | |
| SCHEMBL11390014 | 0.88 | ALDH1A1 (0.50) | ATMKDM4EALDH1A1DRD2SLC6A4 | |
| SCHEMBL5445367 | 0.85 | ATM (0.43) | ATMKDM4EALDH1A1IDO1TDO2 | |
| SCHEMBL5438058 | 0.85 | ATM (0.43) | ATMKDM4EALDH1A1IDO1TDO2 | |
| Flosequinan SCHEMBL7451233 | 0.84 | ATM (0.40) | ATMALDH1A1GSK3BPRKCASCN9A | |
| SCHEMBL7317623 | 0.84 | TP53 (0.38) | KDM4EALDH1A1GSK3BPRKCACDK2 | |
| SCHEMBL5864364 | 0.83 | ATM (0.43) | ATMKDM4EALDH1A1IDO1TDO2 | |
| SCHEMBL5864473 | 0.83 | ATM (0.43) | ATMKDM4EALDH1A1IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1404 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022187317-A1 | THERAPEUTIC FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION | THE UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2022-09-09 | — | — | WO | claimed |
| EP-3681497-A1 | PROTEIN KINASE C INHIBITION TO EXTEND TISSUE PLASMINOGEN ACTIVATOR TREATMENT FOR ISCHEMIC DISEASE | The Regents of The University of Michigan (US) | 2020-07-22 | — | — | EP | claimed |
| US-20200147137-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | WUGEN, Inc. | 2020-05-14 | — | — | US | claimed |
| WO-2019055589-A1 | PROTEIN KINASE C INHIBITION TO EXTEND TISSUE PLASMINOGEN ACTIVATOR TREATMENT FOR ISCHEMIC DISEASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-03-21 | — | — | WO | claimed |
| US-20190076510-A1 | PROTEIN KINASE C INHIBITION TO EXTEND TISSUE PLASMINOGEN ACTIVATOR TREATMENT FOR ISCHEMIC DISEASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-03-14 | — | — | US | claimed |
| US-20150374749-A1 | COMBINATION OF NITROPRUSSIDE AND A SULFIDE SALT AS AN HNO-RELEASING THERAPEUTIC FOR THE TREATMENT OR PREVENTION OF CARDIOVASCULAR DISEASES | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2015-12-31 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2014122074-A1 | COMBINATION OF NITROPRUSSIDE AND A SULFIDE SALT AS AN HNO-RELEASING THERAPEUTIC FOR THE TREATMENT OR PREVENTION OF CARDIOVASCULAR DISEASES | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2014-08-14 | — | — | WO | claimed |
| EP-2764868-A1 | Combination of nitroprusside and a sulfide salt as an HNO-releasing therapeutic for the treatment or prevention of cardiovascular diseases | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2014-08-13 | — | — | EP | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| EP-0527720-A1 | THERAPEUTIC AGENTS. | BOOTS CO PLC (GB) | 1993-02-24 | — | — | EP | claimed |
| EP-0317149-B1 | PROCESS FOR THE SYNTHESIS OF 3-THIO-4-QUINOLONE DERIVATIVES AND INTERMEDIATE COMPOUNDS FOR USE THEREIN, AND THEIR USE AS MEDICAMENTS | The Boots Company PLC (GB) | 1991-11-06 | — | — | EP | claimed |
| US-5011931-A | For treatment of cardiovascular disorders; hypotensive agents | THE BOOTS COMPANY PLC (GB) | 1991-04-30 | — | — | US | claimed |
| WO-1990010445-A1 | THERAPEUTIC AGENTS | THE BOOTS COMPANY PLC (GB) | 1990-09-20 | — | — | WO | claimed |
| EP-0343206-A1 | PROCESS FOR THE SYNTHESIS OF 3-THIO-4-QUINOLONE DERIVATIVES AND INTERMEDIATE COMPOUNDS FOR USE THEREIN, AND THEIR USE AS MEDICAMENTS | The Boots Company PLC (GB) | 1989-11-29 | — | — | EP | claimed |
| WO-1989004827-A1 | PROCESS FOR THE SYNTHESIS OF 3-THIO-4-QUINOLONE DERIVATIVES AND INTERMEDIATE COMPOUNDS FOR USE THEREIN, AND THEIR USE AS MEDICAMENTS | THE BOOTS COMPANY PLC (GB) | 1989-06-01 | — | — | WO | claimed |
| EP-0317149-A1 | Process for the synthesis of 3-thio-4-quinolone derivatives and intermediate compounds for use therein, and their use as medicaments | The Boots Company PLC (GB) | 1989-05-24 | — | — | EP | claimed |
| US-4552884-A | Method of treating heart disease | THE BOOTS COMPANY PLC (GB) | 1985-11-12 | — | — | US | claimed |
| EP-0149519-A2 | Use of quinolones for the manufacture of a composition for the treatment of heart failure. | The Boots Company PLC (GB) | 1985-07-24 | — | — | EP | claimed |
| US-4302460-A | 4-Quinolinones having antihypertensive activity | THE BOOTS COMPANY LIMITED (GB) | 1981-11-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374749-A1 | COMBINATION OF NITROPRUSSIDE AND A SULFIDE SALT AS AN HNO-RELEASING THERAPEUTIC FOR THE TREATMENT OR PREVENTION OF CARDIOVASCULAR DISEASES | NPPA, NOS3, NHERF1 | ATM 2820/4885KDM4E 4649/4885ALDH1A1 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.